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Abstract
Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma and is notorious for its heterogeneity,
aggressive nature, and the frequent development of resistance and/or relapse after treatment with standard
chemotherapy. To address these problems, a strong emphasis has been placed on researching the molecular origins
and mechanisms of DLBCL to develop effective treatments. One of the major insights produced by such research is
that DLBCL almost always stems from genetic damage that occurs during the germinal center (GC) reaction, which is
required for the production of high-afﬁnity antibodies. Indeed, there is signiﬁcant overlap between the mechanisms
that govern the GC reaction and those that drive the progression of DLBCL. A second important insight is that some of
the most frequent genetic mutations that occur in DLBCL are those related to chromatin and epigenetics, especially
those related to proteins that “write” histone post-translational modiﬁcations (PTMs). Mutation or deletion of these
epigenetic writers often renders cells unable to epigenetically “switch on” critical gene sets that are required to exit the
GC reaction, differentiate, repair DNA, and other essential cellular functions. Failure to activate these genes locks cells
into a genotoxic state that is conducive to oncogenesis and/or relapse.

Clinical aspects of diffuse large B-cell lymphoma
Deﬁnition and epidemiology

Diffuse large B-cell lymphoma (DLBCL) is a hematological malignancy derived from mature B-cells that have
undergone (or continue to undergo) the germinal center
(GC) reaction in response to antigen and Helper T-cell
stimulation. The name “DLBCL” stems from the fact that
it consists of large, neoplastic B-cells that are diffusely
spread throughout lymph nodes and, in some cases,
extranodal tissues. The designation of DLBCL as a lymphoma means that it arises from lymphoid rather myeloid
cells and is a solid rather than a “liquid” malignancy (e.g.,
leukemia). Speciﬁcally, DLBCL is classiﬁed as a type of
Non-Hodgkin’s lymphoma (NHL).
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For context, in 2019, NHL is estimated to be the
seventh-most common type of cancer in the U.S., with an
estimated 74,200 new cases that represent ~4.2% of all
new cancer cases (SEER 1, https://seer.cancer.gov/
statfacts/html/all.html). Data recorded between 2012
and 2016 in the U.S. show that NHL has an incidence rate
of 19.6 per 100,000 persons per year and, in 2016, had an
estimated prevalence of 694,704 patients (SEER 2, https://
seer.cancer.gov/statfacts/html/nhl.html).
Speciﬁcally,
DLBCL is the most common subtype of NHL, accounting
for 25–30% of NHL cases in the U.S.1–3. (UpToDate 1,
https://www.uptodate.com/contents/epidemiologyclinical-manifestations-pathologic-features-anddiagnosis-of-diffuse-large-b-cell-lymphoma), and is also
the most common type of lymphoma overall1 (UpToDate
1,
https://www.uptodate.com/contents/epidemiologyclinical-manifestations-pathologic-features-anddiagnosis-of-diffuse-large-b-cell-lymphoma). Based on
the same 2012–2016 U.S. dataset, DLBCL has an incidence rate of 5.6 per 100,000 persons per year overall and
is more common in males (6.7 per 100,000 persons) than
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in females (4.6 per 100,000 persons) (SEER 3, https://seer.
cancer.gov/statfacts/html/dlbcl.html). While there is no
consensus on what causes the discrepancy between the
incidence rates of DLBCL in males and females, there is
evidence suggesting that differences in sex hormones may
be partially responsible. Results from multiple studies
indicate that pregnancy, live birth, and oral contraceptives
are all associated with a reduced risk of DLBCL in
females. The mechanism by which these effects are
achieved is also unclear, although the direct and indirect
effects of estrogen on multiple types of immune cells have
been proposed4. DLBCL can occur in people of all ages,
but cases are not evenly distributed amongst different age
groups. The median age of diagnosis is 66 years old, with
25.0% of cases occurring between ages 65 and 74, 21.2% of
cases between ages 55 and 64, and 20.1% cases between
ages 75 and 84. The incidence rates of DLBCL in all other
age groups are lower (e.g., 12.3% of cases between ages 45
and 54 and 8.8% of cases over the age of 84) (SEER 3,
https://seer.cancer.gov/statfacts/html/dlbcl.html). DLBCL
is also more common in Hispanics (i.e., Latinos) and
Whites than in Asian/Paciﬁc Islanders, Blacks (i.e., African Americans), and Native Americans/Alaskan Natives
(SEER 3, https://seer.cancer.gov/statfacts/html/dlbcl.
html). In addition to differences in incidence, ethnicity
can also sometimes be associated with differences in
clinical outcome. For instance, African-American DLBCL
patients tend to be younger (mean age 54), are more likely
to present at an advanced stage, and have lower survival
and higher mortality rates5 (UpToDate 1, https://www.
uptodate.com/contents/epidemiology-clinicalmanifestations-pathologic-features-and-diagnosis-ofdiffuse-large-b-cell-lymphoma). Because epidemiological
data for DLBCL (i.e., not the broader classiﬁcation of
NHL) at the global level are scarce6, the data presented
here are limited to the United States. The most comprehensive epidemiological database available for DLBCL is
the United States’ National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) Program.
Clinical presentation and diagnostic workup

Clinically, DLBCL often presents as a fast-growing
symptomatic mass in the neck or abdomen, which is
typically indicative of an enlarged lymph node. It most
commonly occurs as an isolated event (de novo), but it
can also transform from pre-existing lymphoid malignancies, such as follicular lymphoma (FL) and chronic
lymphocytic leukemia (CLL). About 30% of patients also
present with constitutional, or “B” symptoms (e.g., unexplained weight loss, fever, and night sweats), and over 50%
of patients show an increase in their serum level of lactate
dehydrogenase (LDH)7,8 (UpToDate 1, https://www.
uptodate.com/contents/epidemiology-clinicalmanifestations-pathologic-features-and-diagnosis-ofBlood Cancer Journal
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diffuse-large-b-cell-lymphoma). The typical evaluation of
a patient exhibiting symptoms of NHL includes a complete blood count (CBC) with differential, a comprehensive metabolic panel (CMP) (including LDH and uric
acid), tests for hepatitis B and human immunodeﬁciency
virus (HIV), the determination of cardiac ejection fraction,
a positron emission tomography with computed tomography (PET/CT) scan, a bone marrow biopsy (depending
on PET/CT results), and an excisional lymph node biopsy
(UpToDate
2,
https://www.uptodate.com/contents/
evaluation-staging-and-response-assessment-of-nonhodgkin-lymphoma) (UpToDate 3, https://www.uptodate.
com/contents/clinical-presentation-and-diagnosis-ofnon-hodgkin-lymphoma). The lymph node biopsy is
crucial, because morphological analysis and immunophenotyping of affected tissue(s) are required for accurate
diagnosis of DLBCL (UpToDate 1, https://www.uptodate.
com/contents/epidemiology-clinical-manifestationspathologic-features-and-diagnosis-of-diffuse-large-b-celllymphoma). Under the microscope, a lymph node that has
been inﬁltrated by DLBCL usually exhibits a complete loss
of normal structures and compartments (e.g., cortex,
medulla, and follicles) and instead consists of diffuse
sheets of neoplastic B-cells (Fig. 1). Though extensive
morphological variation exists, the cells usually appear
large and atypical, with enlarged nuclei, prominent
nucleoli, and have a proliferation fraction (Ki67+) of over
40%. Immunohistochemistry (IHC) or ﬂow cytometry
should also show that the cells express standard B-cell
markers, including cluster of differentiation (CD)19,
CD20, CD22, CD45, and CD79a. Surface or cytoplasmic
immunoglobulin (usually immunoglobulin M (IgM)) is
expressed in 50–75% of DLBCL tumors as well2,3
(UpToDate
1,
https://www.uptodate.com/contents/
epidemiology-clinical-manifestations-pathologic-featuresand-diagnosis-of-diffuse-large-b-cell-lymphoma).
Staging and subtyping

The results of a patient’s PET/CT scan are used to stage
his/her DLBCL. Since DLBCL is a type of NHL, staging is
conducted according to the Lugano classiﬁcation (Table 1),
which goes by the number and location of tumor sites9,10
(UpToDate
2,
https://www.uptodate.com/contents/
evaluation-staging-and-response-assessment-of-nonhodgkin-lymphoma). Stage I involves one lymph node
region or one extralymphatic site without lymph node
involvement (Stage IE). Stage II involves two or more
lymph node regions on the same side of the diaphragm,
either with (Stage IIE) or without the localized involvement of an extralymphatic site. Together, Stages I and II
constitute limited-stage disease. Stage III involves lymph
nodes on both sides of the diaphragm. Stage IV requires
the diffuse involvement of one or more extralymphatic
organ(s), with or without the involvement of lymph nodes.
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Fig. 1 Comparison of normal and DLBCL-inﬁltrated lymph node histology. (Left) Normal lymph node after hematoxylin and eosin (H&E)
staining. Note the complex and varied architecture. Arrow on the left points to a germinal center within a follicle; both are in the cortex (outer
region). Arrowhead indicates the medulla (inner region). Bottom arrow shows the hilum, where blood and efferent lymph vessels are connected
(Image Source: https://www.pathpedia.com/education/eatlas/histology/lymph_node/images.aspx?6 (Slide 1)). (Right) H&E staining of a lymph node
that has been inﬁltrated by DLBCL. Note the glassy, uniform surface and complete loss of normal structures (Image Source: https://www.
webpathology.com/image.asp?case=822&n=3 (Slide 3)).

Table 1 The Lugano classiﬁcation.
Stage

Involvement

Extranodal status

Limited
I
II

One node or a group of

Single extranodal lesion with

adjacent nodes

no nodal involvement

Two or more nodal groups on

Stage I or II: nodal extent with

the same side of the diaphragm limited contiguous
extranodal involvement
Like Stage II, but with “bulky”

N.A.

II Bulky disease
Advanced
III

Nodes on both sides of the

N.A.

diaphragm; nodes above the
diaphragm (spleen)
IV

Additional non-contiguous extra- N.A.
lymphatic involvement

This is the system that is used to stage NHLs, including DLBCL, based on PET/CT
scan results. Clinical outcomes can be quite different for patients with limitedstage vs. advanced-stage DLBCL (Table based on Table Source: UpToDate 2,
https://www.uptodate.com/contents/evaluation-staging-and-responseassessment-of-non-hodgkin-lymphoma (Table 9) and Cheson et al.10).

Together, Stages III and IV constitute advanced-stage
disease9,10. (UpToDate 2, https://www.uptodate.com/
contents/evaluation-staging-and-response-assessment-ofnon-hodgkin-lymphoma). The Lugano classiﬁcation
sometimes lacks clinical utility, in part because the staging
system from which it was derived (Ann Arbor) was
initially designed for Hodgkin’s lymphoma (HL). Unlike
HL, NHL tends to spread more through the blood than
through the lymphatic system, and most patients diagnosed with aggressive NHL are already at Stage III or IV by
the time that they present with symptoms (50–70% of
DLBCL patients, depending on the reference)2,3,7,8,11,12
Blood Cancer Journal

(UpToDate
1,
https://www.uptodate.com/contents/
epidemiology-clinical-manifestations-pathologic-featuresand-diagnosis-of-diffuse-large-b-cell-lymphoma).
It is now understood that DLBCL also encompasses a
variety of subtypes that are morphologically indistinguishable yet exhibit distinct gene expression proﬁles
and patterns of genetic and epigenetic aberrations.
Though multiple subtyping schemes have been developed13–16, only the original system published by Alizadeh
et al.17 has been ofﬁcially adopted by the World Health
Organization (WHO)2,3. This system uses information
gathered from gene expression proﬁling (GEP)17, IHC
algorithms18,19, or the Lymph2Cx gene expression assay20
to classify DLBCL into two main subtypes based on its
probable cell of origin (COO): germinal center B-cell
(GCB) and activated B-cell (ABC) (UpToDate 4, https://
www.uptodate.com/contents/prognosis-of-diffuse-largeb-cell-lymphoma). A third, minor subtype consists of
cases that cannot be classiﬁed as either GCB or ABC. The
GCB subtype accounts for ~40% of de novo DLBCL cases,
while the ABC subtype and other non-GCB DLBCLs
account for the other ~60% of de novo cases21–23
(UpToDate
5,
https://www.uptodate.com/contents/
initial-treatment-of-advanced-stage-diffuse-large-b-celllymphoma). Clinically, in addition to COO classiﬁcation,
DLBCL is also further stratiﬁed by the presence of BCL2
(B-cell CLL/lymphoma 2), BCL6 (B-cell CLL/lymphoma
6), and MYC (Myelocytomatosis) chromosomal translocations and/or expression, as determined by ﬂuorescent
in situ hybridization (FISH) or IHC, respectively.
Standard treatment and clinical outcomes

The standard treatment for DLBCL is the R-CHOP
chemoimmunotherapy regimen (Rituximab, Cyclophosphamide, Hydroxydaunorubicin (doxorubicin), Oncovin
(vincristine), and Prednisone). Rituximab is a monoclonal
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antibody that binds the CD20 protein on the surface of Bcells and triggers an innate immune reaction, leading to
cellular toxicity (UpToDate 6, https://www.uptodate.com/
contents/rituximab-intravenous-including-biosimilars-ofrituximab-drug-information). Cyclophosphamide is an
alkylating agent that cross-links the strands of DNA and
inhibits DNA replication (UpToDate 7, https://www.
uptodate.com/contents/cyclophosphamide-druginformation). Doxorubicin is an intercalating agent that
binds between DNA base pairs and inhibits DNA replication, DNA repair, and transcription (UpToDate 8,
https://www.uptodate.com/contents/doxorubicinconventional-drug-information). Vincristine is a tubulinbinding agent that inhibits the formation of microtubules
and the mitotic spindle, which prevents the completion of
mitosis (UpToDate 9, https://www.uptodate.com/
contents/vincristine-conventional-drug-information).
And, prednisone is a corticosteroid (glucocorticoid) that
acts as an immunosuppressant and anti-inﬂammatory
agent (UpToDate 10, https://www.uptodate.com/
contents/prednisone-drug-information). Historically, the
CHOP regimen (even before the addition of rituximab)
has been the treatment of choice for DLBCL based on its
performance in clinical trials24–26. Other regimens to
which CHOP was compared failed to demonstrate an
increase in overall survival (OS), disease-free survival
(DFS), or remission rate (RR), and some [e.g., m-BACOD
(methotrexate with leucovorin, bleomycin, cyclophosphamide, vincristine, and dexamethasone) and MACOPB (methotrexate with leucovorin, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin)27] were
associated with an increase in toxicity27–32 (UpToDate 5,
https://www.uptodate.com/contents/initial-treatment-ofadvanced-stage-diffuse-large-b-cell-lymphoma).
The speciﬁcs of R-CHOP therapy, as well as the extent
to which patients respond, vary depending on the stage
and/or molecular subtype of DLBCL. For cases of limitedstage DLBCL (30–40% of patients) (UpToDate 11, https://
www.uptodate.com/contents/initial-treatment-of-limitedstage-diffuse-large-b-cell-lymphoma), molecular subtype
can still be clinically relevant, but it does not guide
decisions related to treatment as much as it does for
advanced-stage DLBCL (UpToDate 11, https://www.
uptodate.com/contents/initial-treatment-of-limitedstage-diffuse-large-b-cell-lymphoma). Instead, an important decision regarding the treatment of limited-stage
DLBCL is whether to use R-CHOP alone or in combination with involved-ﬁeld radiation therapy (IFRT).
National Comprehensive Cancer Network guidelines
published in 2010 (ref. 33) recommended treating limitedstage DLBCL with either three cycles of R-CHOP and
subsequent IFRT or six to eight cycles of R-CHOP (with
or without subsequent IFRT). This has been heavily
debated due to concerns over potentially unnecessary
Blood Cancer Journal
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radiation-induced toxicity. Administration of the former
(3 cycles R-CHOP + IFRT) has been associated with a 5year OS rate of ~95% (though individual patient outcomes
can vary)34, as well as lower acute hematologic and cardiac toxicity (UpToDate 11, https://www.uptodate.com/
contents/initial-treatment-of-limited-stage-diffuse-largeb-cell-lymphoma). However, the latter (6–8 cycles RCHOP − IFRT) is associated with a comparable long-term
survival rate and avoids the risk of long-term radiation
toxicity (UpToDate 11, https://www.uptodate.com/
contents/initial-treatment-of-limited-stage-diffuse-largeb-cell-lymphoma). A recent clinical trial35 (UpToDate 11,
https://www.uptodate.com/contents/initial-treatment-oflimited-stage-diffuse-large-b-cell-lymphoma)
directly
compared the outcomes of R-CHOP (4–6 cycles) with or
without subsequent radiation therapy (RT) in limitedstage (Stage I or II) DLBCL patients. The group that
received RT had a 5-year OS rate of 96%, while the group
that did not receive RT had a 5-year OS rate of 92% (i.e.,
no statistically signiﬁcant difference between groups). The
median time to relapse was also the same for both groups,
as well as cardiac and hematologic toxicity proﬁles, but
three patients in the RT group exhibited symptoms of
radiation-induced toxicity. Therefore, the authors of the
study recommend withholding RT for limited-stage
DLBCL patients who show a complete response (CR) on
PET scan after 4–6 cycles of R-CHOP35 (UpToDate 11,
https://www.uptodate.com/contents/initial-treatment-oflimited-stage-diffuse-large-b-cell-lymphoma).
Overall,
most patients diagnosed with limited-stage DLBCL have
favorable outcomes when treated with R-CHOP, with or
without IFRT.
However, the same cannot always be said for patients
diagnosed with advanced-stage DLBCL (50–70%,
depending on the reference)2,3 (UpToDate 1, https://
www.uptodate.com/contents/epidemiology-clinicalmanifestations-pathologic-features-and-diagnosis-ofdiffuse-large-b-cell-lymphoma). There are likely multiple
reasons for this fact. First, advanced-stage DLBCL is disseminated throughout the body, affecting multiple lymph
node regions and/or organs. Second, advanced-stage
DLBCL contains greater genetic and epigenetic (i.e.,
changes in gene expression that occur without altering the
actual DNA sequence) heterogeneity than does limitedstage DLBCL. Third, advanced-stage disease tends to have
a higher proportion of patients with ABC-type DLBCL,
which is more aggressive and associated with a worse
prognosis than the GCB-type36 (UpToDate 4, https://
www.uptodate.com/contents/prognosis-of-diffuse-largeb-cell-lymphoma). This makes sense, given that the GCB
subtype of DLBCL has instead been observed to be more
enriched in limited-stage disease35,36. And, fourth, the coexpression of MYC and BCL2 (two proto-oncogenes
strongly associated with aggressive lymphomas) is more
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likely in advanced-stage DLBCL and is independently
associated with a worse prognosis36 (UpToDate 4, https://
www.uptodate.com/contents/prognosis-of-diffuse-largeb-cell-lymphoma). A study published in 2015 (ref. 36)
(UpToDate
4,
https://www.uptodate.com/contents/
prognosis-of-diffuse-large-b-cell-lymphoma)
analyzed
biopsies from 344 de novo DLBCL patients (49% limitedstage and 51% advanced-stage) treated with R-CHOP in
order to determine molecular subtype and to assess
subtype-speciﬁc clinical outcomes. Limited-stage patients
had a 5-year OS rate of 86% for the GCB subtype and 69%
for the ABC subtype, whereas advanced-stage patients’ 5year OS rates were 74% for the GCB subtype and 51% for
the ABC subtype. Outcomes were also determined based
on the co-expression of MYC and BCL2, although these
were not stratiﬁed by stage. Patients who were not MYC
+/BCL2+ had a 5-year OS rate of 76% (81% for GCB and
62% for ABC), while those who were MYC+/BCL2+ had
a 5-year OS rate of 54% (64% for GCB and 51% for ABC).
Taken together, these ﬁndings emphasize the need for
molecular subtyping of advanced-stage DLBCL in order
to predict its clinical outcome and choose the most
appropriate treatment. Since the GCB subtype of
advanced-stage DLBCL has a relatively good prognosis (5year OS of 74%)36 (UpToDate 4, https://www.uptodate.
com/contents/prognosis-of-diffuse-large-b-celllymphoma), R-CHOP (6 cycles; 21 days between each
cycle) is still its standard therapy (UpToDate 5, https://
www.uptodate.com/contents/initial-treatment-ofadvanced-stage-diffuse-large-b-cell-lymphoma).
However, due to the poor outcomes of ABC-type advancedstage DLBCL and DLBCLs that co-express MYC and
BCL2 (without chromosomal translocations) in response
to R-CHOP, it is often recommended that these patients
enroll in a clinical trial (UpToDate 5, https://www.
uptodate.com/contents/initial-treatment-of-advancedstage-diffuse-large-b-cell-lymphoma).
Overall, while R-CHOP can achieve relatively effective 5-year OS rates in certain subsets of DLBCL
patients (e.g., limited-stage and GCB-type), ~30% of all
patients either do not respond or relapse within 5 years
of treatment24,25, and 30–50% of all patients are not
cured26,37. Furthermore, while some components of
this regimen do exhibit slight speciﬁcity (Rituximab
targets the B-cell marker CD20; Prednisone targets
inﬂammatory pathways and immune cells), even these
still affect normal cells, and the regimen as a whole
targets rapidly dividing cells indiscriminately. Consequently, recipients of R-CHOP often experience many
of the side effects for which chemotherapy is notorious
(e.g., hair loss, vomiting, and immune suppression). RCHOP’s lack of speciﬁcity is even more problematic in
light of DLBCL’s extensive genetic and epigenetic
heterogeneity. In general, as the heterogeneity of a
Blood Cancer Journal
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cancer increases, the likelihood that a given treatment
will effectively treat all of its subclones decreases.
These conditions can result in a poor initial response to
therapy and/or the selection of chemoresistant subclones that lead to relapse.

Natural history and molecular pathogenesis of
DLBCL
Normal B-cell function

To address the shortcomings of standard DLBCL therapy, researchers in the past couple of decades have placed
greater emphasis on understanding the natural history
and molecular pathogenesis of the disease. Because cancers are derived from normal cells, it would be difﬁcult to
fully comprehend the etiology and behavior of DLBCL
without ﬁrst examining normal B-cells and the principles
that underlie their function. As the cornerstone of
humoral immunity, naive B-cells’ main objectives are to
(1) recognize antigens (from pathogens), (2) produce Bcell receptors (BCRs) with high afﬁnity for antigens, and
(3) differentiate into either memory B-cells (for faster
response to future infections) or plasma cells, which
actively secrete high-afﬁnity antibodies. Humoral immunity is essential for ﬁghting infections and is also the
biological process that makes vaccination possible. A
recent study of circulating B-cells in a cohort of ten
human subjects found that the human antibody repertoire
may contain as many as 1016–1018 unique heavy/lightchain combinations38. Theoretically, this staggering
diversity should enable the body to respond to any foreign
antigen that it may encounter. However, B-cells cannot
accomplish all of these objectives alone or in their initial
state. They must cooperate with dendritic cells and Tcells, progress through a coordinated sequence of modifying events, and survive an intense selection environment, all of which occur during a process known as the
GC reaction.
The GC reaction

The GC reaction (Fig. 2) starts when a mature, naive Bcell encounters an antigen in a secondary lymphoid tissue
(e.g., lymph node). Although the BCR of this cell does
recognize the antigen, its baseline afﬁnity for the antigen
is low. The B-cell migrates to the edge of a lymphoid
follicle, where it presents a peptide from the antigen to
CD4+ T-cells via major histocompatibility complex II
(MHC II). This step is selective, as B-cells with higher
baseline afﬁnity for antigen than their competitors are
preferentially bound by T-cells. After receiving T-cell
stimulation, the B-cell starts proliferating and, then,
relocates to the center of the follicle, where it seeds the
formation of the GC. Once it has matured, the GC contains two distinct compartments: the dark zone (DZ) and
the light zone (LZ). The DZ consists of highly proliferative
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Fig. 2 The germinal center (GC) reaction. The GC reaction is the foundation of humoral immunity. Its end products are memory B-cells and plasma
cells that encode high-afﬁnity antibodies. However, it also is the source of many types of B-cell lymphoma, including DLBCL. The time-lapse panels at
the top of this ﬁgure depict the sequential steps of the GC reaction, which take place within lymph node follicles. The large panel at the bottom
zooms in to show the mechanisms behind, and outcomes of, the selection of GC B-cells by TFH cells in the light zone of the germinal center (Figure
Source: Victora41. See this reference for a detailed review).

B-cells called centroblasts that divide once every 6–12 h39
and undergo random somatic hypermutation (SHM) of
the genes encoding the variable regions of immunoglobulins (IgVs). After dividing 1–6 times40, centroblasts can
transition to the LZ, where the afﬁnity of their newly
modiﬁed BCR for antigen is tested. The LZ consists of
non-replicative B-cells (centrocytes), follicular dendritic
cells (FDCs), and T follicular helper (TFH) cells. A centrocyte ﬁrst receives some of the antigen from an FDC,
whose tendril-like appendages serve as an antigen reservoir. Once the centrocyte processes the antigen, it presents MHC II loaded with peptide to TFH cells. TFH cells
are limited in number, which forces centrocytes to compete with one another. Centrocytes have three potential
paths, and each cell’s outcome is entirely dependent upon
the afﬁnity of its BCR for antigen(s). The “default setting”
of a centrocyte is to undergo apoptosis in the absence of
sufﬁcient T-cell signal (i.e., low afﬁnity). Thus, only centrocytes whose BCRs have high afﬁnity for antigen are
positively selected by TFH cells. Cells that are positively
Blood Cancer Journal

selected then undergo class switch recombination (CSR)
to switch from the default IgM isotype to IgG, IgA, or IgE
(depending on context), followed by differentiation into
memory B-cells or plasma cells. However, 10–30% of
centroctyes41 have BCRs with intermediate afﬁnity for
antigen, which is enough to interact with TFH cells and
avoid apoptosis but not enough for true positive selection.
These cells are instead sent back to the DZ for subsequent
cell divisions and SHM, and they will later be given
another opportunity for positive selection in the LZ. (The
above information was adapted from refs. 39–42. Refer to
these for a more detailed discussion of the topic.)
The GC reaction owes much of its “design” to the
principles of biological evolution, as it marries genetic
combinatorics (baseline antibody diversity + SHM) with a
natural (and clonal) selection environment (positive
selection by TFH cells) to ﬁnd the cells that respond best
to a selective pressure (possess BCRs with the highest
afﬁnity for an antigen). This strategy also resembles
combinatorial optimization, a process used in
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mathematics and computer science to ﬁnd the optimal
solution to a speciﬁc problem from a ﬁnite number of
potential solutions. Though the number of potential
unique antibodies is technically ﬁnite, it is so large that it
likely would not be feasible to systematically test all of
them. As a compromise, different antibodies are modiﬁed
and tested at random until one (or more) is found that
binds a speciﬁc antigen with sufﬁciently high afﬁnity. This
mirrors the logic of evolution, by which “survival of the
ﬁttest” does not necessarily guarantee the greatest of all
possible ﬁts, but rather one that sufﬁciently overcomes a
selective pressure and outperforms its competitors. If
applied in the appropriate context and with strict guidelines, these principles can be quite effective for performing a normal biological function like the GC reaction.
However, as those in the ﬁeld of cancer biology have
known for decades, cancer is also driven by evolutionary
principles and follows a pattern of clonal selection and
evolution43. Viewed from this perspective, it is not difﬁcult to imagine how a system that intentionally recreates a Darwinian microenvironment could (1) cause or
promote oncogenic events, even under “normal” conditions or (2) become pathologically dysregulated and
repurposed as a sort of “operating system” for cancer
cells. Furthermore, the physiological mechanisms that
the GC reaction requires to function are inherently
risky. The transformation from GC B-cells to DLBCL
cells often involves the removal of negative feedback and
temporal restrictions on normal, essential pathways,
without any functional alteration of the protein(s)
involved. In other words, simply upregulating the core
mechanisms of the GC reaction and/or increasing their
duration can sometimes be enough to initiate oncogenesis (as shown in experiments; discussed later).
Along these lines, multiple researchers40,44 have highlighted the fact that B-cells undergoing the GC reaction
naturally exhibit multiple characteristics that resemble
the hallmarks of cancer45.
Activation-induced deaminase and the GC reaction

The GC reaction is complex and multifaceted, but there
are two components in particular that can explain a great
deal about its physiology, the risks inherent to its strategy,
and its sometimes-oncogenic side effects. The ﬁrst component is activation-induced deaminase (AID), an enzyme
that deaminates cytosine residues at speciﬁc sites
throughout the genome. AID is required for both SHM
and CSR46, which are required for making high-afﬁnity
and class-switched antibodies, respectively. This deamination converts cytosines to uracils, which result in U:G
mismatches that trigger DNA repair via the mismatch
repair (MMR) or base excision repair (BER) pathways. For
some genes, especially those that encode IgVs, DNA
repair involves an error-prone DNA polymerase (Pol η).
Blood Cancer Journal
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This increases the rate of mutations, insertions, and
deletions that fuel SHM and the DNA double-stranded
breaks (referred to as DNA-DSBs) that are required for
CSR (although DNA-DSBs can occur during SHM as
well). Perhaps not surprisingly, a mechanism that intentionally causes DNA damage can have serious side effects,
and most B-cell lymphomas can be traced back to cells
that come from the GC and/or have gone through the GC
reaction47. The side effects of the GC reaction primarily
include chromosomal translocations and oncogenic
mutations. Translocations (e.g., MYC, BCL2, and BCL6)
are quite common in B-cell lymphomas and NHLs in
general. They usually involve the intact coding region of a
proto-oncogene being placed under the control of an
immunoglobulin gene regulatory sequence (e.g., enhancer), resulting in constitutive expression. While AID is
suspected to increase the likelihood of DNA-DSBs and
translocations for multiple genes, it has been most ﬁrmly
linked to MYC translocations. In a set of in vivo experiments, Pasqualucci et al. showed that mice engineered to
overexpress BCL6 (master regulator of GCs; see section
titled “BCL6 and the GC reaction”) but which had a
knockout of the gene that encodes AID (AICDA,
activation-induced cytidine deaminase) were incapable of
producing MYC-IGH translocations when stimulated to
undergo CSR. On the contrary, mice overexpressing BCL6
and normally expressing AICDA showed an increase in
the number of MYC-IGH translocations of over tenfold
when compared with wild-type mice. Furthermore, only
~14% (1/7) of tumors in BCL6-overexpressing/AICDAknockout mice (tumor incidence = 7/29, or ~24%) possessed features of DLBCL, compared to ~69% (11/16) of
tumors in BCL6-overexpressing/AICDA-normal mice
(tumor incidence = 16/27, or ~59%)48.
As was mentioned previously, SHM of genes encoding
IgVs is required for the generation of high-afﬁnity antibodies. During SHM, the mutation rate at IgV loci is ~106
times higher than the spontaneous mutation rate
observed in somatic cells49. The B-cells that survive SHM
and selection during the GC reaction beneﬁt from afﬁnity
maturation. Each IgV locus obtains approximately nine
mutations, and the afﬁnity of their antibodies increase by
about 100-fold50. It has been known for quite some time
that the AID-mediated process of SHM does not always
stay within the conﬁnes of IgV loci. This pathological
“mistargeting” of SHM is called aberrant SHM (aSHM).
aSHM does not occur in normal GC B-cells and is unique
to GC-derived B-cell lymphomas, especially DLBCL, of
which over 50% of cases show evidence of aSHM in
multiple proto-oncogenes51. It is still not entirely clear
how aSHM occurs. An interesting study by Liu et al.
found that AID actually targets a variety of genes located
throughout the genome in normal GC B-cells, many of
which are not IgV loci. While a few of these genes (e.g.,
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IgVs) are hypermutated due to DNA “repair” with an
error-prone DNA polymerase, many other genes receive
high-ﬁdelity repair and are left without a trace of AID
activity. This led Liu et al. to propose that aSHM may be
due to a breakdown in the high-ﬁdelity repair of genes
that would otherwise be “protected” under normal circumstances52. Since then, knowledge of the genes that are
targeted by AID and/or aSHM has continued to
expand53,54.
One particular gene that has been studied extensively
with regard to both SHM and aSHM is BCL6 (see above
in this section and below in section titled “BCL6 and the
GC reaction”)55–58. For reasons that are not readily
apparent, BCL6 is the most common non-IgV target of
SHM52,53, with 59–73% of DLBCL cases55,57 and even
~30% of normal GC B-cells57 showing evidence of SHM
in the 5′ noncoding region. Liu et al. showed that,
unlike most of the other non-IgV targets of SHM, BCL6
seems to receive the same error-prone DNA repair as
IgV loci. The mutation rate of BCL6 in wild-type B-cells
is almost as high its mutation rate in cells with
knockouts of key genes involved in MMR and BER52.
Mutations in the 5′ noncoding region can cause the
deregulated expression of BCL6; for instance, in ~13%
of DLBCL cases, such mutations interfere with the
ability of BCL6 to negatively regulate its own expression59. Another ~40% of DLBCL cases involve chromosomal translocations that lead to upregulated BCL6
expression, with breakpoints typically located in the
same 5′ noncoding region60,61 (UpToDate 12, https://
www.uptodate.com/contents/pathobiology-of-diffuselarge-b-cell-lymphoma-and-primary-mediastinal-largeb-cell-lymphoma). Lastly, the expression and/or activity
of BCL6 can also be indirectly upregulated as a result of
mutations in other genes such as MEF2B (myocyte
enhancer factor 2B) and FBXO11 (F-box only protein
11). Regardless of the speciﬁc mechanism by which it
occurs, the deregulation of BCL6 expression is very
common in DLBCL.
BCL6 and the GC reaction

Similarly to AID, the actions of BCL6 are strongly
associated with both the GC reaction and the oncogenic
transformation of GC B-cells. BCL6 is highly expressed in
GC B-cells and is often referred to as the master regulator
of the GC reaction. Results from multiple studies have
shown that the expression of BCL6 is required for GC
formation and antibody afﬁnity maturation62,63. BCL6 is a
transcriptional repressor whose function is to reduce or
prevent the expression of genes whose encoded products
would otherwise interfere with the GC reaction (Fig. 3).
Recall that GC B-cells must be able to tolerate an enormous amount of DNA damage in order for the processes
of SHM and CSR to work, despite the fact that cells are
Blood Cancer Journal
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ordinarily on high alert for signs of DNA damage. In GC
B-cells, this conﬂict between preserving genomic integrity
and creating high-afﬁnity, class-switched antibodies is
mediated in large part by BCL6. BCL6 accomplishes this
by repressing the transcription of TP53 (tumor protein
53), ATM (ataxia telangiectasia mutated), ATR (ataxia
telangiectasia and Rad3 related), CHEK1 (checkpoint
kinase 1), and CDKN1A (cyclin-dependent kinase inhibitor 1A, or p21), all of which are critical for signaling and
triggering a response to DNA damage, including stopping
the cell cycle, initiating high-ﬁdelity DNA repair, and/or
inducing apoptosis. BCL6 also represses genes involved in
other essential aspects of the GC reaction. These include
PRDM1 (PR/SET domain 1), which is required for the
terminal differentiation of GC B-cells into memory B-cells
or plasma cells, and the genes encoding microRNAs
(miRs) miR-155 and miR-361, which negatively regulate
the expression of AICDA. Thus, BCL6 and AID can
positively regulate each other. (For a thorough review of
BCL6’s functions, mechanisms, and targets, see Hatzi and
Melnick’s review44).
It is not hard to imagine how a system that (1) increases
cells’ tolerance of DNA damage, (2) permits rapid progression through the cell cycle, and (3) prevents terminal
differentiation, could be compromised and repurposed as
a powerful survival mechanism for cancer cells. Using a
mouse model engineered to constitutively express BCL6,
Cattoretti et al. found evidence in support of BCL6’s role
in the pathogenesis of DLBCL64. Compared to wild-type
mice, BCL6-overexpressing mice had a signiﬁcantly
greater number of GCs in splenic tissue after immunization and produced ~30% fewer plasmacytoid cells (mostly
post-CSR plasma cells), indicating altered post-GC differentiation. By 6 months of age, 42% of the BCL6-overexpressing mice developed a benign lymphoproliferative
disease, compared to 11% in wild-type mice. At
13 months of age, the BCL6-overexpressing mice started
to exhibit increased mortality. Between 15 and 20 months
of age, 36–62% of BCL6-overexpressing mice had developed B-cell lymphoma (compared to 2–8% in wild-type
mice), and 75% of these cases resembled DLBCL. Overall,
by 20 months of age, 76–89% of BCL6-overexpressing
mice had either lymphoproliferative disease or lymphoma
(compared to 8–14% in wild-type mice), as well as a signiﬁcant decrease in survival64.
It is striking that this same protein can be both required
for the GC reaction and a driver of GC-derived lymphoma, simply by deregulating its expression without any
functional alteration. It seems that this system has evolved
with an “awareness” of the oncogenic potential of BCL6,
as it is normally restrained by multiple regulatory
mechanisms. BCL6 can inhibit its own expression via
negative feedback (see section titled “AID and the GC
reaction”), and it is also downregulated and targeted for
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Fig. 3 Functional interactions between proteins relevant to GC B-cell and DLBCL physiology. BCOR BCL6 corepressor; FBXO11 F-box only
protein 11; BCL2 B-cell CLL/lymphoma 2; TP53 tumor protein 53; CDKN1A cyclin-dependent kinase inhibitor 1A; CDKN1B cyclin-dependent kinase
inhibitor 1B; MEF2B myocyte enhancer factor 2B; BCL6 B-cell CLL/lymphoma 6; PRDM1 PR/SET domain 1; MYC myelocytomatosis; ATM Ataxia
telangiectasia mutated; ATR Ataxia telangiectasia and Rad3-related protein; CHEK1 checkpoint kinase 1; MDM2 murine double minute 2; IRF4
interferon regulatory factor 4; AICDA activation-induced cytidine deaminase (Figure prepared using: STRING Protein-Protein Interactions Network
(https://string-db.org)).

degradation by multiple signaling pathways in response
to high-afﬁnity BCR-antigen binding and positive
selection by TFH cells42,65,66. The expression of BCL6
must be shut off and is not normally expressed in postGC cells, because one of its main targets, PRDM1, is
required for GC exit and differentiation. Interestingly,
BCL6 also represses the transcription of a number of
proto-oncogenes, including MYC and BCL2 (ref. 67).
MYC is critical for cyclic reentry of LZ centrocytes back
into the DZ for further replication and SHM. BCL2 is an
anti-apoptotic factor that further increases the threshold
for programmed cell death. In their review of BCL6,
Hatzi and Melnick propose that the repression of MYC
and BCL2 by BCL6 may be an attempt to compensate for
its repression of tumor suppressor genes44. It may also
partly explain why MYC and BCL2 translocations are
not uncommon in DLBCL, as they allow escape from
BCL6 repression44.
Blood Cancer Journal

The genetic heterogeneity of DLBCL

As one might expect of a cancer derived from cells and
an environment centered around combinatorial diversity,
heterogeneity is a deﬁning characteristic of DLBCL. This
can be observed all the way from its clinical outcome, to
its cellular morphology and phenotype, and down to its
molecular proﬁle, where DLBCL demonstrates a staggering amount of genetic and epigenetic heterogeneity.
Starting at the genetic level, numerous studies over the
past decade have analyzed hundreds of DLBCL patients’
tumor genomes in an effort to better understand the
molecular pathogenesis of the disease15,16,68–73. Mutations
have been found in more than 700 different genes39, with
each case of DLBCL having an average of 50–100 genetic
lesions in the coding genome69,71,72,74. Approximately 150
of these genes are mutated in >5% of patients and considered genetic drivers of DLBCL, with an average of ~8
driver mutations per case73. A genomic analysis of more
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than 92,000 cases of over 100 types of cancer found that
DLBCL had the fourth-highest tumor mutational burden
(TMB), with a median of 10 mutations per megabase (Mb)
of DNA and ~18% cases with >20 mutations/Mb75. Of the
ten cancer types with the highest TMB in this study,
DLBCL (#4) and FL (#8; can transform into DLBCL) are
the only ones which are not epithelial (i.e., carcinomas) or
melanocytic (i.e., melanoma) in nature. Furthermore, all
other cancers in the “top 10” besides DLBCL and FL are
derived from the lung, skin, or melanocytes, all of which
are highly associated with exogenous sources of DNA
damage (e.g., smoking and UV light)75. This further corroborates the notion that the occurrence of DLBCL is
largely due to endogenous (but still powerful) sources of
DNA damage76.
Endogenous sources of mutation and their signatures

Chapuy et al. recently analyzed the mutational signatures in the genomes of 304 DLBCL patients’ tumors in
an attempt to identify the source(s) of mutations in
recurrently affected genes16. Approximately 80% of all
mutations were linked to the spontaneous deamination of
cytosines at CpGs and a switch from cytosine to thymine
(C > T). This type of mutation is associated with aging
and, accordingly, the tumors of older patients in this
cohort had more mutations with this signature than did
younger patients’ tumors. This ﬁnding also aligns with the
fact that DLBCL patients are usually diagnosed at an older
age (median 66 years old) (SEER3, https://seer.cancer.gov/
statfacts/html/dlbcl.html). Two other mutational signatures were prominent in this study as well. One signature, termed “canonical AID (cAID),” was linked to an
increase in C > T/G mutations at AID hotspots and was
associated with both SHM and aSHM77. The other,
termed “AID2,” had similarities to a non-canonical AID
signature that is linked to an increase in A > T/C/G
mutations and is associated with error-prone DNA repair
subsequent to cytosine deamination by AID77. The contribution of each mutational process varied depending on
the particular gene, with some genes (e.g., BCL2) being
mutated mostly by the cAID and AID2 processes, and
other genes (e.g., NOTCH2) being mutated almost
exclusively by “aging”. It is interesting to note that these
two AID mutational signatures are similar to the ones
initially described by Liu et al.; one involves high-ﬁdelity
DNA repair, and the other involves error-prone DNA
repair52. It should also be noted that mutations caused by
spontaneous deamination (C > T) and cAID (C > T/G) can
remove methylated cytosines, thereby reducing DNA
methylation and altering cells’ epigenetic proﬁles. Multiple studies have even implicated AID-induced DNA
demethylation as a means of epigenetic reprogramming
that promotes pluripotency78–81. The relationship
between AID and DNA methylation will be revisited in
Blood Cancer Journal
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the section titled “Connections between epigenetic dysregulation and relapse in DLBCL”. Presently, however, a
broader discussion of the epigenetic landscape in DLBCL
is warranted.
Frequent mutations in genes related to chromatin and
epigenetics

One of the most consistent trends that has emerged
from genomic analyses of DLBCL is the recurrence of
mutations in genes whose products are speciﬁcally related to chromatin and epigenetics (Fig. 4). Of the 150
genetic drivers of DLBCL described by Reddy et al., 21
(i.e., 14%) of them ﬁt this description (#1 MLL2; #4
HIST1H1E; #6 CREBBP; #10 ARID1A; #15 ARID1B; #16
SETD1B; #18 SMARCA4; #33 SETD2; #34 TET2; #37
ARID5B; #38 EZH2; #43 EP300; #44 MLL3; #54 INO80;
#55 CHD8; #58 DNMT3A; #71 NCOR1; #75 CHD1; #88

Fig. 4 Functional interactions between proteins relevant to GC Bcell and DLBCL epigenetics. SET SET nuclear proto-oncogene; EP300
E1A binding protein 300; DNMT3A DNA methyltransferase 3A; NCOR2
nuclear receptor corepressor 2; ARID1A AT-rich interaction domain 1A;
CREBBP CREB-binding protein; EZH2 Enhancer of zeste 2; DICER1 Dicer
1, ribonuclease III; CBX8 Chromobox 8; CBX1 Chromobox 1; HIST1H1E
histone cluster 1 H1 family member E; TET2 Tet methylcytosine
deoxygenase 2; KMT2D lysine methyltransferase 2D (Figure prepared
using: STRING Protein-Protein Interactions Network (https://string-db.
org)).
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SETD5; #115 DICER1; #128 HIST1H2BC)73. This subset
of genes is skewed toward the top of the list, with 18/21
(86%) located in the “top 75,” 7/21 (33%) in the “top 20,”
and 4/21 (19%) in the “top 10,” including the #1 most
commonly altered gene in DLBCL: MLL2 (alternative
name for KMT2D (lysine methyltransferase 2D)). The
functions of these genes include regulation of DNA
methylation (e.g., DNMT3A) and demethylation (e.g.,
TET2), miRNA processing (e.g., DICER1), chromatin
remodeling (e.g., ARID1A), linker histone-mediated
chromatin compaction (e.g., HIST1H1E), and posttranslational modiﬁcation (PTM) of histones (e.g.,
KMT2D). This last functional category, consisting of
histone-modifying enzymes, are some of the most common mutations in DLBCL69,70,73 and are integral to both
the physiology of the GC reaction and the molecular
pathogenesis of DLBCL.
As was just stated, KMT2D (sometimes called MLL2 or
MLL4) is the most commonly mutated gene in DLBCL,
with ~25% of cases showing genetic alteration73. KMT2D
is a histone methyltransferase that is primarily responsible
for the monomethylation of lysine 4 of histone H3
(H3K4me1), an epigenetic mark that is associated with
active gene enhancers. CREBBP (CREB-binding protein;
~11%) and EP300 (E1A binding protein 300; ~6%) are
genetically altered in ~17% of DLBCL cases, usually in a
mutually exclusive fashion due to their high structural and
functional homology (although CREBBP mutations are
more frequent)73. These two genes encode the eponymous lysine acetyl transferases (KATs; previously called
histone acetyltransferases (HATs)) that acetylate lysines
18 and 27 of histone H3 (H3K18Ac and H3K27Ac), the
latter of which is required for gene enhancer activation.
CREBBP and EP300 also acetylate a variety of non-histone
targets, including BCL6 and p53; the signiﬁcance of this
will be revisited later (see section titled “The epigenetic
switch at enhancers”).
EZH2 (Enhancer of Zeste 2), the enzymatic subunit of
PRC2 (polycomb repressor complex 2), is a histone
methyltransferase that is responsible for the mono-, di-,
and trimethylation of lysine 27 of histone H3
(H3K27me1/2/3), all of which contribute to regulating
promoters’ availability to transcriptional machinery.
About 6% of all DLBCL cases feature mutations in EZH2
(ref. 73). However, unlike mutations in KMT2D, CREBBP,
and EP300 (refs. 68,70), mutations in EZH2 only occur in
the GCB subtype, not the ABC subtype. Within the GCB
subtype speciﬁcally, as many as ~22% cases possess an
EZH2 mutation82. Mutations in EZH2 are always heterozygous, and they almost always target tyrosine residue
641 (Y641) within the enzyme’s catalytic site82. This alters
the enzymatic activity of EZH2 and causes it to favor the
trimethylation of H3K27 over mono- or dimethylation.
The remaining wild-type EZH2 allele is responsible for
Blood Cancer Journal
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providing most of the H3K27 mono- and dimethylation
that cells still require and probably explains why EZH2
mutations are exclusively heterozygous in DLBCL83.
Referring back to the analysis of mutational signatures
in DLBCL by Chapuy et al., it is interesting to note that
these mutations in histone-modifying genes are enriched
in the “aging” signature, albeit to varying degrees.
Approximately 90% of KMT2D and EP300 mutations in
their dataset were linked to aging, as well as ~70% of
CREBBP mutations and >50% of EZH2 mutations16. The
potential implications of this ﬁnding will be discussed
later on in this review. (See sections titled “Endogenous
sources of mutations and their signatures” and “Connections between epigenetic dysregulation and relapse in
DLBCL”.)

Epigenetics determinants of DLBCL
Epigenetic switches in GC B-cells

It has been established that B-cells must progress
through a speciﬁc sequence of steps during the GC
reaction. Some of these steps, such as the transition from
naive B-cell to centroblast in the DZ, are straightforward
and proceed only in one direction. Other steps, however,
require decisions to be made and have multiple potential
outcomes. For instance, as centroblasts move from the DZ
to the LZ, they face the decision of either going through
CSR and becoming plasmacytes or returning to the DZ for
subsequent rounds of cell division and SHM. Some GC Bcells have to cycle between the DZ and LZ multiple times
before they are allowed to proceed to CSR. Furthermore,
once centrocytes go through class-switching and exit the
GC reaction as plasmacytes, they still must commit to
differentiation and decide whether to become memory Bcells or plasma cells. All of these transitions and decisions
require speciﬁc alterations in cellular function and identity, which are made possible by rapid and highly coordinated changes in the expression of particular subsets of
genes. This is especially true for GC-B cells that cycle
between the DZ and LZ, as they must be able to switch
between the gene expression patterns that distinguish
centroblasts from centrocytes at will, and sometimes
repeatedly. GC B-cells achieve this level of plasticity using
a system of epigenetic “switches” that govern the GC
reaction through the addition or removal of speciﬁc histone PTMs at the promoter or enhancer sequences of
genes that require up- or downregulation (for an in-depth
discussion, see Jiang and Melnick’s review84).
Critically, the addition and removal of histone PTMs are
reversible, which allows cells to “toggle” between “on” and
“poised” (i.e., temporarily off, or paused) states of gene
expression efﬁciently and without fully repressing genes
that may soon be needed again. The two epigenetic
switches, one located at promoters and the other at
enhancers, are essential for the normal physiological
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function of GC B-cells and are also very commonly dysregulated during the pathogenesis of DLBCL. In fact,
many of the proteins that are responsible for maintaining
and operating the two epigenetic switches are encoded by
genes that are some of the most frequently mutated in
DLBCL, including KMT2D, CREBBP, EP300, and EZH2.
Additionally, the all-important BCL6 exerts its repressive
effects at the promoters or enhancers of target genes by
forming complexes with histone-modifying enzymes that
alter the epigenetic landscape. Thus, the molecular
pathogenesis of DLBCL can be better understood by
examining these epigenetic switches and how they are
differentially regulated in normal versus pathological
conditions.
The epigenetic switch at promoters

During the GC reaction, BCL6 represses the expression
of over 1000 genes in order to avoid triggering cell-cycle

inhibition, apoptosis, or differentiation before the process
of afﬁnity maturation is complete40,44. BCL6 can repress
the expression of a gene by binding either its promoter or
enhancer, but the sets of genes that are affected by binding
at either location are largely non-overlapping. The precise
mechanism by which BCL6 represses gene expression also
differs depending on whether it is acting at a promoter or
an enhancer85. BCL6 does not act alone. Rather, it must
collaborate (either directly or indirectly) with other proteins in order to exert its repressive effects, many of which
are histone-modifying enzymes. With regard to the epigenetic code, the promoter of a gene is “on” when the
nucleosomes packaging the promoter sequence are decorated with H3K4me3 but not H3K27me3. Conversely,
when these nucleosomes are decorated with H3K27me3
but not H3K4me3, the promoter is considered “off.” When
these nucleosomes possess both H3K4me3 and H3K27me3
(i.e., bivalent chromatin), the promoter is “poised” (Fig. 5).
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Fig. 5 Epigenetic switches at promoters and enhancers in GC B-cells. Starting, maintaining, and exiting from the GC reaction requires rapid and
coordinated changes in the expression of speciﬁc subsets of genes in response to cell signals. This is achieved by using epigenetic switches at the
promoters and enhancers of these genes. (A) H3K4me3 at a promoter signiﬁes that it is “on” (green). The addition of H3K27me3 by EZH2 switches it
to a “poised” (yellow) state of transient repression. The Y641 EZH2 mutation increases H3K27me3 deposition and turns the promoter “off”
permanently (red). (B) H3K27Ac at an enhancer means that it is active. Removal of H3K27Ac by HDAC3 (complexed with BCL6-SMRT) leaves only
H3K4me1 marks behind and poises the enhancer. Inactivation of CREBBP switches enhancers off by preventing their reactivation via H3K27 (and
BCL6) acetylation, leaving HDAC3 unopposed. (C) H3K4me1 is also present at active enhancers. The lysine demethylases KDM1 and KDM5 are
thought to remove H3K4 methylation and poise enhancers. KMT2D inactivation silences enhancers by preventing the addition of H3K4me1. (D) TET2
demethylates cytosines at enhancers, ﬁrst by converting 5-methylcytosine (5mC; repressive) to 5-hydroxymethylcytosine (5hmC; active). TET2
inactivation switches enhancers off by preventing demethylation and, instead, causing hypermethylation. Genes whose promoter and/or enhancer
cannot be reactivated makes them unresponsive to important cell signals. This locks cells into the GC reaction, which can lead to lymphomagenesis
(Figure based on work by Mlynarczyk et al.40).
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Referenced earlier (see section titled “Frequent mutations in genes related to chromatin and epigenetics”), the
histone methyltransferase EZH2 is required for GC formation and afﬁnity maturation86. The main role of EZH2
in the GC reaction is the de novo deposition of
H3K27me3 at the promoters of speciﬁc target genes that
are already marked with H3K4me3 (i.e., active), thereby
forming bivalent promoters. Just like BCL6, some of the
key genes that EZH2 targets include PRDM1 and IRF4,
which are required for the differentiation of GC B-cells
into memory B-cells and plasma cells, as well as CDKN1A
and CDKN1B, which are cell-cycle inhibitors86,87. There is
signiﬁcant overlap between the gene sets that EZH2 and
BCL6 target88,89. Based on their experiments, Béguelin
et al. recently proposed a model whereby BCL6 and EZH2
collaborate in the repression of common target genes by
acting jointly at promoters89. Initially, BCL6 binds its
target sequence within the promoter, and EZH2 (as part
of PRC2) independently increases the level of H3K27me3
at the promoter. The CBX8 (chromobox 8) subunit of
PRC1 (polycomb repressor complex 1) then binds to
H3K27me3, as PRC1 is typically the protein complex that
is responsible for H3K27me3-mediated transcriptional
repression. However, in GC B-cells, many of the canonical
components of PRC1 are downregulated while other,
non-canonical components such as BCOR (BCL6 corepressor) are upregulated. When CBX8 (as part of PRC1)
binds to H3K27me3, it brings the PRC1–BCOR complex
along with it. This promotes the interaction of BCOR and
BCL6 to form a BCL6–BCOR complex. While BCL6 and
EZH2 act on the promoter independently and do not
make physical contact, their simultaneous action allows
for a “combinatorial tethering” that is required for the
stable binding of BCOR to BCL6. Stable formation of the
BCL6–BCOR complex at poised promoters is what allows
the expression of these genes to be temporarily
repressed89.
Previous experiments by Hatzi et al. showed that BCL6
is also capable of forming a ternary complex with both
BCOR and SMRT (silencing mediator of retinoid and
thyroid hormone receptors; also called NCOR2, or
nuclear corepressor 2) at the promoters of certain genes
in DLBCL cells85. This BCL6–SMRT–BCOR complex was
shown to more strongly repress the expression of target
genes than the BCL6–BCOR complex, but it was bound to
the promoters of far fewer genes (n = 341) than the BCL6BCOR complex (n = 1783). Furthermore, a principal
component analysis (PCA) determined that BCL6 actively
repressed promoters only when it was bound to BCOR
and SMRT (i.e., ternary complex) and when accompanied
by a particular chromatin signature (decreased H3K4me3,
H3K36me3, H3K79me2, and H3K9Ac; increased
H3K27me3 and DNA methylation) that is associated with
pausing of RNA polymerase II elongation85.
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In cases of DLBCL that feature constitutive expression
of BCL6 and a mutation in EZH2 that increases its
deposition of H3K27me3 (e.g., Y641), the resulting state
of repression becomes permanent rather than transient.
While it is necessary to temporarily repress the expression
of genes whose products would interfere with the GC
reaction, prolonging their repression indeﬁnitely greatly
increases the risk of oncogenesis. Béguelin et al. observed
this in their experiments when they bred mice that constitutively express BCL6 and possess the EZH2 Y641
mutant allele89. The bone marrow of these mice, as well as
that of three different types of control mice, were then
transferred to four separate groups of lethally irradiated
mice. The mice who received bone marrow from the
BCL6-overexpressing, EZH2-mutant donors experienced
a dramatic acceleration in their mortality compared to all
of the other mice. The BCL6-overexpressing, EZH2mutant recipients also displayed clear evidence of either
lymphoma (10/12; FL or DLBCL) or pre-neoplastic lymphoid neoplasia (2/12) upon both gross pathological and
histopathological inspection, while none of the mice from
the other three groups (wild-type controls (0/4), EZH2mutant only (0/4), and BCL6-overexpressing only (0/5))
showed any evidence of disease89.
The epigenetic switch at enhancers

Just like promoters, enhancers also have an epigenetic
code that inﬂuences their level of activity. An enhancer is
only considered “on” when nucleosomes are decorated
with H3K27Ac, although H3K4me1 is typically found at
active enhancers as well90. An enhancer that loses
H3K27Ac but retains H3K4me1 is considered “poised.”
And, an enhancer that has neither H3K27Ac nor
H3K4me1 marks is considered “off” (Fig. 5). CREBBP and
P300 are responsible for depositing H3K27Ac at enhancers, which activates them. CREBBP/P300 and BCL6SMRT compete with each other at enhancers and can cooccupy enhancers, and upregulation of BCL6 is associated
with a decrease in P300 binding at enhancers in GC Bcells85. BCL6 arguably plays a more direct role in the
repression of enhancers, and it is bound to more enhancers than promoters in GC B-cells85. When BCL6 binds to
its target sequence at an enhancer, it must form a complex similar to the one that it does at promoters in order
to enact its repression. However, unlike at promoters,
BCL6 only binds SMRT and does not bind BCOR, which
is structurally unrelated to SMRT and binds through a
different peptide sequence85,91,92. Critically, the SMRT
corepressor is bound to histone deacetylase 3 (HDAC3),
which deacetylates H3K27 and switches active enhancers
to a poised state with only H3K4me1 marks remaining85.
Subsequent experiments by Jiang et al. investigated the
effects that inactivating CREBBP mutations have on the
“balance of power” between CREBBP/P300 and the BCL6-
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SMRT-HDAC3 complex at the enhancers of certain genes
in GC B-cells93. Their results show that CREBBP inactivation prevents the deposition of H3K27Ac at enhancers
that are poised (i.e., have had H3K27Ac removed) during
the GC reaction, which prevents both enhancer reactivation and proper expression of the genes that they regulate. Jiang et al. also show that, due to its removal of
CREBBP-mediated acetylation, the action of HDAC3 at
enhancers is required to properly initiate the GC reaction.
In the absence of H3K27 acetylation by CREBBP, HDAC3
activity is left unopposed, and DLBCL cells become
HDAC3-dependent for survival. When DLBCL cells with
knocked-down CREBBP expression were treated with a
selective HDAC3 inhibitor, H3K27 acetylation at the
enhancers of multiple MHC II genes was rescued. The
subsequent expression of those MHC II genes was also
rescued. It should also be noted that wild-type CREBBP/
P300 can acetylate BCL6 as a form of negative regulation
by preventing its association with HDACs94. Conversely,
acetylation of p53 by wild-type CREBBP/P300 is a form of
positive regulation, as it prevents the ubiquitination of
p53 by murine double minute 2 (MDM2)95. The ability of
CREBBP/P300 to acetylate both BCL6 and p53 is strongly
inhibited by mutations that inactivate their HAT
domain68,94. Thus, in addition to the loss of regulatory
inﬂuence at enhancers that accompanies CREBBP/P300
inactivation, GC B-cells also lose their ability to directly
regulate p53 and BCL6, both of which are integral to GC
physiology and DLBCL pathology.
Importantly, the subset of enhancers that are affected by
CREBBP inactivation strongly overlaps with the subset of
enhancers that are bound by the BCL6–SMRT–HDAC3
complex. Some of the most notable genes whose enhancers were affected by CREBBP inactivation (and, thus,
unopposed HDAC3 repression) in these experiments are
those involved in GC exit and termination, plasma cell
differentiation, and MHC II antigen processing and presentation93. The impact of CREBBP inactivation on these
particular pathways is further corroborated by experiments independently conducted by Zhang et al.96. Their
results show that Crebbp deletion in murine GC B-cells
results in decreased expression of certain genes that, in
human GC B-cells, are also (1) expressed, (2) marked with
H3K27Ac, and (3) bound by CREBBP. Many of these
genes are related to signaling pathways (e.g., BCR, CD40,
NF-kB, chemokines, cytokines, and lymphocyte migration) that are activated in the LZ96. As was reviewed
earlier (see section titled “The GC reaction”), the LZ is
where B-cells whose BCR afﬁnity for antigen is sufﬁciently
high can be directed to go back to the DZ for further
modiﬁcation or to differentiate into memory B-cells or
plasma cells. Furthermore, their data from ChIP-seq
(chromatin immunoprecipitation followed by DNA
sequencing) experiments demonstrate the same dynamic
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of CREBBP and BCL6 opposition at the promoters and/or
enhancers of genes that are strongly related to initiating,
maintaining, and/or exiting the GC reaction. These
include genes involved in the cell cycle, responding to
DNA damage, apoptosis, differentiation, and multiple
signaling pathways, such as BCR, NF-kB, Toll-like
receptor (TLR), interferon (IFN), and activation by
T-cells96.
Taken together, all of these ﬁndings depict a scenario in
which GC B-cells that possess inactivating CREBBP/P300
mutations can become locked into the GC reaction and
unresponsive to the signals that would normally terminate
the GC reaction and determine their fate. Those genes
whose expression is incompatible with successful afﬁnity
maturation, namely those required for DNA damage
response, apoptosis, immune recognition, GC exit, and
differentiation, cannot be switched back on due to an
inability to restore proper H3K27 acetylation at enhancers. In this state, GC B-cells are denied the opportunity
to differentiate and perform their intended biological
function, while continuing to be exposed to highly
mutagenic and potentially oncogenic internal conditions.
Functional effects of CREBBP deﬁciency

Multiple studies, including some of those discussed
above, have documented the functional effects of CREBBP
deﬁciency and its contribution to lymphomagenesis. For
instance, Zhang et al.96 compared the ability of murine
splenic B-cells with wild-type, heterozygous, or
homozygous-deleted Crebbp to terminally differentiate
ex vivo. After stimulating cells with lipopolysaccharide
(LPS) and interleukin 4 (IL4), ﬂow cytometry showed that
~8.5% of wild-type B-cells exhibited a plasmablastic
phenotype (pre-plasma cell; high CD138 and low B220),
while only ~3% of B-cells with a heterozygous or homozygous deletion of Crebbp showed the same plasmablastic
ﬂow cytometry signature. Results from qRT-PCR experiments also showed a signiﬁcant decrease in Prdm1
(required for terminal differentiation) expression in
Crebbp-deleted (hetero- and homozygous) vs. wild-type
cells. Flow cytometry of splenic B-cells taken from a
separate cohort of mice after immunization with sheep
red blood cells (SRBCs) also showed a signiﬁcant decrease
in the percentage of high-CD138/low-B220 B-cells in
Crebbp-deleted (hetero- and homozygous) vs. wild-type
mice. Additional ﬂow cytometry experiments demonstrated that Crebbp-deleted (hetero- and homozygous)
splenic B-cells showed higher levels of proliferation and
viability as well when compared to wild-type cells. Lastly,
they investigated the direct effect of Crebbp deletion on
the lymphomagenesis in mice in vivo. Deletion of Crebbp
on its own was not enough to cause a statistically signiﬁcant increase in lymphoma incidence, although 3/22
cases in the heterozygous knockout group (vs. 0/20 in
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wild-type and 0/24 in homozygous knockout groups) did
develop lymphoma (two DLBCL and one FL). However, in
mice with both a heterozygous Crebbp deletion and
deregulated Bcl2 expression (which frequently co-occur in
FL and DLBCL), there was a signiﬁcant increase in lymphoma incidence, with 92% (22/24) of these mice developing some type of FL, compared to 61.5% (16/26) in mice
with deregulated Bcl2 expression but wild-type Crebbp96.
Likewise, Hashwah et al. investigated the effects of
CREBBP mutation/deletion on GC B-cell proliferation
and lymphomagenesis97. Starting with in vitro experiments, CRISPR (clustered regularly interspaced short
palindromic repeats) was used to introduce an inactivating mutation to one CREBBP allele in a wild-type human
DLBCL cell line. While this did result in decreased H3K18
acetylation and changes in gene expression, especially
those involved in MHC II antigen processing and presentation, no signiﬁcant difference in growth rate as a
function of CREBBP status was observed. However, when
human DLBCL cells with wild-type or heterozygousmutant CREBBP were subcutaneously xenografted onto
mice, the tumors consisting of CREBBP-mutant cells grew
faster and had a greater mass than tumors of wild-type
CREBBP cells. Moreover, orthotopic xenografts established intravenously using the same human DLBCL cells
with wild-type or heterozygous-mutant CREBBP showed
a greater capacity for engraftment in the bone marrow of
both immunocompromised mice and mice with a
humanized immune system. In separate experiments,
groups of mice were engineered to delete one or both
alleles of Crebbp or Ep300 in response to AID activity
after SRBC immunization97. Heterozygous and homozygous Crebbp-deleted mice exhibited hyperproliferation
of GC B-cells while, interestingly, the opposite occurred
for mice with heterozygous and homozygous deletions of
Ep300. Histopathological analysis of splenic tissue showed
that the increase or decrease in the number of GC B-cells
was due to an increase or decrease of the size of GCs,
respectively. Lastly, they also wanted to assess the extent
to which loss of Crebbp contributes to lymphomagenesis.
Similar to the ﬁndings of Zhang et al.96, heterozygous
Crebbp deletion was not sufﬁcient to induce lymphomagenesis by itself. However, mice with both a heterozygous
deletion of Crebbp and constitutive expression of Myc
developed lymphoma earlier (~20 days post-immunization) and had worse OS (12.5%; 1/8) than mice with wildtype Crebbp and constitutive Myc expression (~60 days
post-immunization; 50%; 2/4)97.
Finally, in addition to the more mechanistic experiments described earlier in this section, Jiang et al. studied
the functional effects of Crebbp loss93. Hematopoietic
progenitor cells (HPCs) were isolated from mice with
deregulated Bcl2 expression, transduced with either a
control retrovirus or one that expresses anti-Crebbp
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shRNA (short hairpin RNA), and then transplanted to
lethally irradiated wild-type mice. The lymphomas of mice
that received HPCs with knocked-down expression of
Crebbp displayed an earlier onset and a more aggressive,
invasive phenotype than lymphomas with normal Crebbp
expression. A similar phenotype was also observed when
the same experiments were performed with Ep300
knockdown93. In summary, the results of these functional
studies support a role for the loss of CREBBP in promoting increased GC B-cell proliferation, GC expansion,
decreased terminal differentiation, greater aggression and
invasiveness, and an increased capacity for lymphomagenesis when combined with the deregulated expression
of known oncogenes. In many instances, the loss of EP300
has similar effects, although this is not always the case.
Functional effects of KMT2D deﬁciency

It was alluded to previously (see section titled “The
epigenetic switch at enhancers”) that, while the presence
or absence of H3K27Ac at nucleosomes along an
enhancer is what ultimately distinguishes between its “on”
and “off” states, respectively, H3K4me1 is also typically
present at active enhancers. Furthermore, in the absence
of H3K27Ac, the presence of H3K4me1 at an enhancer
signiﬁes that it is in a “poised” state rather than completely “off.” KMT2D is responsible for the mono-, di-,
and trimethylation of H3K4, which it accomplishes
through its catalytic SET (Su(var)3–9, Enhancer-of-zeste,
and Trithorax) domain. Since KMT2D is the most commonly mutated gene in DLBCL, multiple investigations
have been conducted in order to better understand the
molecular and functional effects of KMT2D mutations, as
well as their impact on lymphomagenesis.
Zhang et al. compared the in vitro methyltransferase
activity of 16 different KMT2D mutants derived from
DLBCL98. Eleven mutants showed a signiﬁcant decrease
in activity, most of which (9/11) had a mutation close to
the SET domain and were among the most severely
affected. These results were validated in vivo by measuring genome-wide levels of H3K4me1, H3K4me2, and
H3K4me3 in splenic B-cells from mice with wild-type,
heterozygous-deleted, or homozygous-deleted Kmt2d.
Heterozygous mice showed a small increase in all three
(H3K4me1/2/3), while those with a complete loss of
Kmt2d showed a sharp decrease in H3K4me1/2/3. A
similar pattern was observed in a panel of human DLBCL
cell lines, except that heterozygous cell lines also showed a
decrease in H3K4me1/2/3. Mice with homozygous loss of
Kmt2d also experienced changes in B-cell development
after SRBC immunization, including signiﬁcantly fewer
B220+ B-cells in lymphoid tissues, mature B-cells in the
bone marrow, and follicular B-cells in the spleen. The
formation of GCs was also affected in SRBC-immunized
mice with homozygous loss of Kmt2d. These mice
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exhibited signiﬁcant increases in their GC B-cell population and the number, average size, and total area of GCs.
The results in mice with a heterozygous deletion of
Kmt2d were similar to those of mice with complete
Kmt2d loss but were generally of lesser magnitude. The
relative depletion of cells that precede GC B-cells (e.g.,
follicular B-cells) and expansion of GC B-cells and GCs
that occur in these mice suggest that loss of Kmt2d
encourages mature B-cells to enter the GC reaction more
readily. Separate ex vivo experiments also showed that
splenic B220+ B-cells taken from Kmt2d-deﬁcient mice
also display a greater proliferative rate than wild-type
cells. This observation ﬁts with results from gene
expression analyses showing that the transcriptional signature in cells that have lost Kmt2d is enriched in genes
that are involved in cell-cycle regulation and apoptosis98.
Lastly, the extent to which Kmt2d loss directly inﬂuences
lymphoma incidence and pathogenesis was tested in mice
with wild-type, heterozygous-deleted, and homozygousdeleted Kmt2d. Similar to the ﬁndings of Zhang et al. and
Jiang et al. in their studies of CREBBP93,96, deletion of
Kmt2d alone was not enough to signiﬁcantly increase
lymphomagenesis (0/23 wild-type, 0/22 heterozygousdeleted, and 0/15 homozygous-deleted mice). However, in
mice with both loss of Kmt2d and deregulated Bcl2
expression, lymphoma incidence increased from 44.4%
(12/27) in wild-type mice to 62.5% (15/24) in heterozygous mice and 78.6% (22/28) in homozygous mice, with
cases ranging from early FL to DLBCL98.
In an independent study, Ortega-Molina et al. also
investigated the inﬂuence of Kmt2d deﬁciency on lymphomagenesis in multiple mouse models99. First, HPCs
obtained from mice with deregulated Bcl2 expression
were transduced with either a control or anti-Kmt2d
shRNA-expressing retrovirus and transplanted into lethally irradiated wild-type mice. Those who received HPCs
with knocked-down Kmt2d expression in addition to
increased Bcl2 expression exhibited early onset of lymphoma, splenomegaly, and histopathological evidence of
high-grade FL. A second mouse model, in which Kmt2d
was knocked out completely, resulted in 58% of them
becoming diseased compared to 0% in wild-type controls.
The affected mice developed a lymphoma consisting of
atypical pre-GC B-cells that had not undergone SHM or
CSR. While the disease was not quite comparable to
human lymphomas (e.g., FL and DLBCL), the results do
support a role for KMT2D as a tumor suppressor. The
third mouse model was designed to overexpress Aicda in
addition to having a complete deletion of Kmt2d. Recall
from earlier that Aicda encodes AID, which is essential for
both the GC reaction and GC-derived lymphomas. All
mice (7/7; 100%) developed lymphoma, whereas all of the
mice overexpressing Aicda without Kmt2d deletion
remained lymphoma-free (0/14; 0%)99. The onset of
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disease in affected mice was even earlier than in mice with
Kmt2d deletion alone, and tumors displayed greater
aggression and wider dissemination within the spleen and
other organs. Evidence of SHM, CSR, and a plasmacytic
phenotype were also present, none of which were
observed in mice with Kmt2d deletion only. Experiments
studying the effects of Kmt2d deletion on B-cell development produced results similar to those of Zhang
et al.98. After SRBC immunization, there was a signiﬁcant
decrease in follicular B-cells and signiﬁcant increases in
transitional B-cells (also observed before immunization)
and GC B-cells in the spleen. Using the same HPC
transplant model described above, recipients of HPCs
with knocked-down Kmt2d expression also exhibited
prolonged GC formation in the spleen after SRBC
immunization compared to wild-type mice. Furthermore,
in vivo and in vitro experiments showed evidence of
reduced CSR from IgM to IgG1 after immunization/stimulation in the B-cells of Kmt2d-knockout mice. These
results differ from those of Zhang et al., which found an
increase in IgG1+ B-cells but an approximately tenfold
decrease in antigen afﬁnity (though different antigens
were used)98. Gene expression studies of KMT2D-mutant
FL in humans and lymphoma in Kmt2D-deﬁcient mice
revealed a strong overlap between their sets of affected
genes (compared to wild-type), especially those that are
downregulated99. Notably, this overlap included genes
involved in immune signaling (e.g., IL and TNF) and
plasma cell differentiation. ChIP-seq experiments were
also performed in murine Kmt2d-deﬁcient lymphomas
and human KMT2D-mutant lymphoma cell lines (compared to wild-type) in order to map changes in H3K4me1/
2 distribution and associated changes in gene expression.
In both mouse and human lymphomas, global levels of
H3K4me1/2 did not decrease, but losses at speciﬁc loci
were detected, especially at enhancers. In mice, some of
the genes most affected by reduced H3K4me1/2 at promoters and enhancers were those that are induced by
immune signaling (e.g., IL, TNF, NF-kB, and CD40);
enhancer-speciﬁc H3K4me1/2 loss also overlapped with a
variety of downregulated tumor suppressor genes. In
human cells, genes that lost H3K4me1/2 and are known
KMT2D binding targets were also heavily enriched for
immune signaling pathways (e.g., IL, NF-kB, CD40, and
IRF4). Lastly, multiple KMT2D target genes were studied
in order to trace the direct connections between KMT2D
mutation/loss and the functional effects that occur
downstream. Many genes, such as tumor necrosis factor
alpha-induced protein 3 (TNFAIP3), require BCR and
CD40 signals for expression in B-cells. TNFAIP3 encodes
a protein (A20) that has been shown to negatively regulate
NF-kB activity and promote apoptosis in non-Hodgkin
lymphomas100. In human DLBCL cell lines with knockeddown KMT2D expression, the level of H3K4me1/2 at the
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enhancer of TNFAIP3 (signiﬁcantly) and its expression
(not signiﬁcantly) both decreased. Moreover, induction of
TNFAIP3 expression and cell apoptosis by BCR and
CD40 signaling were both signiﬁcantly decreased; these
same results were observed in a comparison of KMT2Dmutant and KMT2D-wild-type human lymphoma cell
lines, as was the absence of any signiﬁcant effect on cell
proliferation99. Thus, similar to the results of CREBBP
inactivation that were discussed earlier (see section titled
“The epigenetic switch at enhancers”), KMT2D loss/
inactivation appears to make B-cells less responsive to
CD40 signaling and less able to switch on genes that are
required for important cell fate decisions.
Overall, the results of these functional studies suggest a
multifaceted role for the loss/inactivation of KMT2D in
the progression of lymphoma, especially in FL and
DLBCL. The effects of its loss include increased proliferation, resistance to BCR and CD40 signaling, an
expansion of GC B-cells at the expense of follicular Bcells, increased and prolonged formation of GCs, greater
aggression, wider dissemination, and an increased capacity for lymphomagenesis when cooperating with other
oncogenes. Finally, as an interesting side-note, although
KTM2D is not directly involved in the acetylation or
deacetylation of H3K27Ac, experiments in mouse
embryonic stem cells and preadipocytes have shown that
KMT2D (i.e., the protein itself, not H3K4 methylation) is
required for CREBBP/P300 to bind and activate enhancers
that regulate the expression of genes involved in terminal
differentiation and cell identity101–103. Without jumping
to conclusions, it would be interesting to know if mutations that result in decreased or lost KMT2D expression
in GC B-cells also result in decreased CREBBP/P300
recruitment to and activation of enhancers in GC B-cells
and/or lymphoma.
Connections between epigenetic dysregulation and
relapse in DLBCL

It is clear that mutations in histone-modifying enzymes
like KMT2D, CREBBP, P300, and EZH2 are some of the
most common in DLBCL and that they contribute directly
to its molecular pathogenesis. The same can be said for
FL, which can transform into and shares many similarities
with DLBCL. There is a growing body of evidence suggesting that, in many instances, these are driver mutations
that occur early on and help create an environment that is
more conducive to oncogenesis. Moreover, these mutations are very commonly present in both early tumor cells
and those that are selected during relapse or transformation from FL to DLBCL, thus indicating strong evolutionary ﬁtness104–108.
For example, Jiang et al. compared matched pairs of
tumors taken from 14 DLBCL patients, both at diagnosis
and at relapse subsequent to R-CHOP therapy107. After
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analyzing the clonal heterogeneity of each sample and
comparing each diagnostic tumor to its corresponding
relapse tumor(s), two major patterns of clonal evolution
were identiﬁed. The ﬁrst was an “early-divergent” pattern
in which the diagnosis and relapse clones were derived
from a common precursor but diverged early on in
development and occupied separate branches of the
phylogenetic tree. The second was a “late-divergent”
pattern in which the diagnosis and relapse clones occupied the same branch of the phylogenetic tree and
retained a high degree of similarity. On average, earlydivergent tumors had signiﬁcantly greater entropy (i.e.,
clonal heterogeneity) at diagnosis than did late-divergent
tumors. Furthermore, while the diagnosis subclones of
early-divergent tumors were almost non-existent in
relapse tumors, the diagnosis subclones of late-divergent
tumors largely maintained their presence in relapse
tumors. Exome sequencing was also performed on half of
the matched pairs of tumors, including 3/6 from the earlydivergent group. From an epigenetic perspective, the
results from early-divergent tumors were particularly
interesting, as all three pairs possessed mutations in
histone-modifying enzymes in both the diagnosis and
relapse tumors. Pair 1 had mutations in both KMT2D and
SETDB1 (SET domain bifurcated histone lysine methyltransferase 1), pair 2 had a mutation in KMT2D as well,
and pair 9 had a mutation in EP300. Additionally, some of
the relapse tumors contained additional chromatinmodifying/associated proteins that were not present at
diagnosis. For pair 1, it was a mutation in TET2 (tet
methylcytosine deoxygenase 2), pair 2 had a mutation in
EP300, and pair 9 added a mutation in BRD4 (bromodomain-containing protein 4). TET2, along with TET1
and TET3, comprise the family of ten-eleven translocation (TET) that directs the convoluted process of cytosine
demethylation. They catalyze the successive conversion of
5-methylcytosine (5mC) to 5-hydroxymethylcytosine
(5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine
(5caC), the latter two of which can trigger DNA repair
and replacement with unmethylated cytosine109. Like
AID, TET2 initiates a biological process that leads to
reduced DNA methylation (Fig. 6) and an altered epigenome (see section titled “Endogenous sources of
mutation and their signatures”). As a result of TET2 loss,
hematopoietic cells and acute myeloid leukemia (AML)
cells displayed selective hypermethylation and inactivation of enhancers in one study110. Additionally, loss of
TET2 in GC B-cells was recently shown to mirror many of
the mechanistic and functional effects observed in
CREBBP-mutant DLBCL, including enhancer inactivation
and inhibition of GC exit and plasma cell differentiation111 (Fig. 5).
BRD4 is an epigenetic “reader” that binds to acetylated
histones and serves as a general transcription cofactor and
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Fig. 6 DNA repair and de-methylation pathways. Cytosine (C) methylation to 5-methyl cytosine (5-mC) is mediated by DNA-methyl transferases
(DNMT) through direct transfer of CH3. De-methylation is a far more complex process, involving ten-eleven translocation (TET) enzymes, base
excision repair (BER), and thymine DNA glycolase (TDG). Transition from C to uracil (U) or thymine (T) can also be involved in this complex process,
through using activation-induced cytidine deaminase (AID) and apolipoprotein B mRNA-editing enzyme catalytic (APOBEC), and mismatch repair
(MMR) (adapted from Bhutani et al.80 and Dominguez and Shaknovich120). 5-hmC: 5-hydroxy methyl cytosine; 5-fC: 5-formyl cytosine; 5-caC: 5carboxyl cytosine; 5-hmU: 5-hydroxy methyl uridine.

partners with many transcription factors that promote
gene expression. It is heavily involved in the organization
and activation of super-enhancers, especially those that
regulate the expression of genes that maintain cell identity. Interestingly, BRD4 is also involved in DNA repair
and is required to complete CSR in B-cells after the
introduction of DNA-DSBs by AID112. Additionally, one
of the four late-divergent matched pairs of tumors (pair 8)
also gained a mutation in a histone-modifying enzyme
(EZH2) that was present only at relapse, not at diagnosis.
Speciﬁcally, it was the Y641 EZH2 mutation, which disproportionately increases the deposition of H3K27me3 at
the expense of H3K27me1/2, as reviewed earlier (see
section titled “Frequent mutations in genes related to
chromatin and epigenetics”). These ﬁndings, as well as
those observed in FL104, led Jiang et al. to propose a model
of DLBCL development and relapse in which mutations in
epigenetic modiﬁers can serve as (1) early “driver”
mutations that disrupt the epigenome in a way that favors
lymphomagenesis and/or (2) “facilitator” mutations that
occur later in development and introduce characteristics
that favor relapse107. It was mentioned previously that
EZH2, CREBBP, EP300, and KMT2D mutations in
DLBCL predominantly have a signature of spontaneous
cytosine deamination (C > T) that is associated with
aging16. (See section titled “Frequent mutations in genes
related to chromatin and epigenetics.”) Though it would
Blood Cancer Journal

need be shown deﬁnitively, this observation may further
support the idea that mutations in histone-modifying
enzymes can occur early on in the process (as a byproduct
of aging; not sufﬁcient for lymphomagenesis) and “set the
stage” for lymphomagenesis later on.
This review of DLBCL epigenetics has focused primarily
on histone-modifying enzymes because of their high
mutation rates and their relevance to GC B-cell physiology and pathology. However, it is important to emphasize
the role that DNA methylation plays in DLBCL84,113–121.
Speciﬁcally, Pan et al. found that higher levels of DNA
methylation heterogeneity in DLBCL tumors at the time
of diagnosis could predict relapse subsequent to R-CHOP
therapy116. Relapse was also accompanied by a decrease in
intra-tumor DNA methylation heterogeneity, suggesting
clonal selection. Furthermore, relapse was not correlated
with clonal genetic heterogeneity, at least with regard to
SHM patterns at VDJ sequences116. Additionally, Teater
et al. recently published results from in vivo experiments
in mice showing that AID itself is a driver of DNA
methylation heterogeneity118 (Fig. 7). This implicates AID
not only in the most essential steps of afﬁnity maturation
in normal GC B-cells, but also in the production of
genetic and epigenetic heterogeneity during lymphomagenesis. The results of these studies make sense in light of
what is known about AID’s involvement in DNA demethylation and epigenetic reprogramming. (See section
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Fig. 7 Activation-induced cytidine deaminase (AID), DNA methylation and epigenetic heterogeneity in DLBCL and other types of
lymphoma. Activation of naïve B-cells (NBC) transitioning to normal germinal center B-cells (NGBC). Changes in DNA methylation patterns during
differentiation (GC reaction) involve AID (see Fig. 6), which strongly contributes to creating epigenetic heterogeneity ultimately leading to disease
progression and potentially aggressivity. Gray rectangle: promoter region; broken arrow; transcription start site (TSS); open circles: CG hypomethylation; closed circles: CG hyper-methylation; gray circles: intermediate CG methylation state: 5-hmC, 5-fC, 5-caC, brown oval: CTCF, green oval:
methyl-DNA binding proteins; ++: high expression; +: medium expression; +/−: Low expression: +/− −: very low expression; X: repressed.

titled “Endogenous sources of mutation and their
signatures.”)
Viewing DLBCL as a disease of epigenetic dysregulation

When attempting to synthesize all of these disparate
ﬁndings regarding the epigenetic dysregulation of DLBCL,
it is hard not to notice parallels with the epigenetic progenitor model of cancer proposed by Feinberg et al. in
2006 (refs. 121–124). Their model proposes that cancer
really begins as a disruption of the epigenome in the stem/
progenitor cells of a normal tissue prior to explicit
oncogenesis. This produces a polyclonal population of
cells that are epigenetically perturbed and begin gradually
drifting toward oncogenesis. Epigenetic disruption could
be caused by “tumor-progenitor genes” that “mediate
epigenetic expansion of progenitor cells… and increase
their cancer proneness, …” possibly by prioritizing stemness over differentiation122. Feinberg et al. speciﬁcally
propose AICDA as a candidate tumor-progenitor gene
because it acts on DNA directly, causes both genetic and
epigenetic changes, and has been linked to B-cell lymphomagenesis. (See sections titled “Endogenous sources
of mutation and their signatures” and “Connections
between epigenetic dysregulation and relapse in DLBCL.”)
They also point toward genes whose products directly
modify chromatin, such as EZH2. Eventually, chronic
epigenetic disruption leads to an initiating genetic
Blood Cancer Journal

mutation that formally drives oncogenesis, followed by
further genetic and epigenetic aberrations. From then on,
the cancer begins to increasingly emphasize the acquisition of genetic and epigenetic plasticity125, or “adaptability,” in order to more readily adapt to any conditions
that it may encounter. For example, epigenetic instability
is caused by changes in the expression of genes whose
products modify chromatin, like EZH2. One could plausibly argue that changes in the activity of chromatinmodifying enzymes, including EZH2, CREBBP, P300 and
KMT2D, may also lead to epigenetic instability123,124.
Increased plasticity, in turn, fuels tumor heterogeneity
and allows cancer cells to experiment with a diverse array
of phenotypes and more aggressive characteristics (Fig. 8).
This increases the entropy of the system and decreases the
probability that any one therapy will kill every single
subclone, which can lead to chemoresistance121,126. Once
again, this sequence of events sounds quite similar to that
which occurs during the development of DLBCL, a cancer
notorious for both its heterogeneity and its resistance to
treatment.
Additionally, it is evident that DLBCL is closely associated with aging. As was previously mentioned, the
median age of diagnosis is 66 years old, and 66.3% of
DLBCL cases occur between the ages of 55 and 84 (SEER
3, https://seer.cancer.gov/statfacts/html/dlbcl.html). Furthermore, ~80% of genetic mutations in DLBCL have a
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Fig. 8 Epigenetic heterogeneity promotes the acquisition of aggressive traits in cancer. Classically, cancer has been thought of as a disease
that is primarily genetic in nature. However, it is now known that epigenetic dysregulation in cancer can also be functionally and clinically relevant.
One clear example is its contribution to tumor heterogeneity. When the epigenome is disrupted, either independently of genetic mutations (e.g.,
AID-related DNA hypomethylation) or as a result of them (e.g., in histone-modifying enzymes), tumor cells can start to evolve based on selection for
favorable epigenetic states. This can lead to the production of tumor subclones that are genetically identical but, in reality, are expressing different
combinations of genes and/or have altered the level at which certain genes are expressed. In addition to producing more aggressive characteristics,
increased tumor heterogeneity decreases the likelihood that any one treatment will be able to kill every subclone, which can lead to
chemoresistance and relapse (Based on work by Easwaran et al.126).

signature that is associated with aging16. It should be
noted that the aging process itself is known to involve
extensive epigenetic reprogramming. This includes such
events as the loss of heterochromatin, changes in the
levels of certain histone variants, alterations in the levels
and distributions of histone PTMs and DNA methylation,
and differential expression of noncoding RNAs127. It
seems quite likely that the aging process contributes to
the development of DLBCL in some patients, perhaps
acting as an accelerant with regard to large-scale epigenetic reprogramming.
For all of these reasons, an enormous amount of both
basic-science and clinical research has been devoted to
ﬁnding alternative strategies for the treatment of DLBCL
besides the standard R-CHOP chemotherapy regimen,
especially those that target the epigenome128–132. Because
epigenetic modiﬁcations are reversible, the ideas of
reprogramming oncogenic epigenetic changes in
DLBCL133 and preventing the transformation of precancerous B-cells123 are very appealing (This is the logic
behind our on-going investigation into the effects of diet
(i.e., ω-3 fatty acids) on the epigenome in DLBCL.).
Theoretically, it stands to reason that “resetting” the
epigenome of DLBCL cells could also potentially reduce
tumor heterogeneity by eliminating subclones that are
genetically identical but epigenetically distinct. Furthermore, if the drug doses were low enough to alter the
epigenome and reduce tumor heterogeneity without killing cells, then perhaps it would be possible to shape the
Blood Cancer Journal

cancer’s characteristics and overall “trajectory” without
promoting natural selection and the development of
resistance. This would not eliminate the tumor mass itself,
but if used rationally, perhaps some of its more aggressive
characteristics and/or propensity for relapse could be
reduced133. Much more research is needed to develop
therapies for DLBCL that address its immense complexity
in a way that R-CHOP chemotherapy simply does not.
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